Leaflet GLUBRAVA 15mg / 850mg film-coated tablets
Indicated for: type 2 diabetes mellitus
Route of administration: oral
Substance: pioglitazone + metformin (thiazolidinedione antidiabetic + biguanide antidiabetic)
ATC: A10BD05 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
Dose adjustment may be needed in kidney disease.
Periodic laboratory tests may be required during treatment.
Use during pregnancy only on medical advice.
The combination of pioglitazone and metformin is used in the treatment of type 2 diabetes to improve glycemic control. Pioglitazone works by increasing insulin sensitivity, while metformin reduces hepatic glucose production and improves glucose utilization by muscles.
The medication is taken orally, as directed by a doctor, usually once or twice daily with meals. It is important for patients to follow the treatment regimen and adopt a healthy lifestyle, including a balanced diet and regular exercise.
Patients should be aware of potential side effects, such as nausea, diarrhea, or weight gain. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, and weight gain. In rare cases, severe reactions such as lactic acidosis or liver failure may occur. Patients should be informed of these risks before use.
General data about GLUBRAVA 15mg / 850mg
- Substance: pioglitazone + metformin
- Date of latest medicines list: 01-07-2013
- Product code: W51458007
- Concentration: 15mg / 850mg
- Pharmaceutical form: film-coated tablets
- Quantity: 90
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.